Novo Nordisk Bolsters Obesity Pipeline With $2.6 Billion Hengrui Licensing Deal

Novo Nordisk signs a licensing deal worth up to $2.6 billion for an oral obesity drug and presents Ozempic and CagriSema data at EASD.

Novo Nordisk has moved to deepen its metabolic disease portfolio on two fronts, signing an exclusive licensing pact for an experimental oral obesity drug while rolling out fresh clinical data on its flagship combination therapy at Europe's largest diabetes conference.

The Danish drugmaker finalized an agreement with China's Hengrui Pharma on September 29 for worldwide rights to HRS-1596, an oral dual GLP-1/GIP receptor agonist that is on the cusp of entering Phase 1 human trials. The deal excludes mainland China, Hong Kong, Macau and Taiwan, and carries a potential total value of up to $2.6 billion, including a $300 million upfront payment to the Chinese partner.

The tie-up marks a push by Novo Nordisk into pill-based weight-loss treatments, a segment still dominated by injectable products even as patient demand shifts toward easier-to-administer options. By adding a dual-action mechanism to its early-stage pipeline, the company is positioning itself for longer-term competition in the obesity market.

Ozempic Tops Mounjaro on Cardiovascular Outcomes

Separately, Novo Nordisk used the annual meeting of the European Association for the Study of Diabetes (EASD) to present a real-world analysis pitting its top-selling Ozempic against Eli Lilly's rival therapy. Among adults with type 2 diabetes, treatment with a 2-milligram dose of semaglutide was linked to a lower risk of major adverse cardiovascular events than switching to tirzepatide, sold as Mounjaro.

The findings hand the Danish group a key talking point in the fast-growing market for incretin mimetics, where it is locked in a direct battle with its U.S. competitor. Tirzepatide targets additional receptors beyond GLP-1, and the real-world data reinforce the cardiovascular credentials of Ozempic, a cornerstone of Novo Nordisk's diabetes franchise.

CagriSema Data Highlights Brain and Organ Effects

Also at EASD, Novo Nordisk detailed new results for CagriSema, its closely watched combination candidate. A one-year study showed altered brain responses to tempting food cues among participants, alongside a reduction in the persistent food-related thoughts known as "food noise." In adults with type 2 diabetes, the therapy cut fat accumulation around internal abdominal organs, while early findings indicated that bone health remained stable despite the weight loss achieved. Reducing organ fat is viewed in cardiology and diabetology as an important lever for lowering long-term health risks.

The company additionally pointed to analyses showing that Wegovy normalized liver fat levels in nine out of ten patients with excess liver fat.

FDA Extends Review of Hemophilia Candidate

Away from its core diabetes and obesity business, Novo Nordisk ran into a regulatory snag. The U.S. Food and Drug Administration has extended its review of Denecimig, a hemophilia A candidate, because manufacturing deficiencies at a production site need to be resolved. The agency did not provide a new decision timeline, though it raised no concerns about clinical efficacy or safety data. Novo Nordisk continues to target a U.S. launch for Denecimig in the first half of 2027 and said the delay does not affect its full-year 2026 financial guidance.

Investor Caution Weighs Against Pipeline Wins

The regulatory holdup comes as management seeks to convince investors of its long-term trajectory. At a capital markets day in London roughly three weeks ago, executives outlined ambitions for revenue growth through 2030 broadly in line with that of large pharmaceutical peers. According to Reuters, reservations voiced by investors over pricing power and the company's acquisition strategy dampened sentiment at the event.

Market participants are now weighing solid clinical results against regulatory setbacks and questions over long-term margins. In Friday trading on European exchanges, Novo Nordisk shares added 0.9% to change hands at EUR 34.26.